tiprankstipranks

Prometheus downgraded to Neutral from Outperform at Credit Suisse

Credit Suisse analyst Tiago Fauth downgraded Prometheus (RXDX) to Neutral from Outperform with a $200 price target after Merck (MRK) announced plans to acquire the company for $10.8B in cash, or $200 per share.

Confident Investing Starts Here:

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on RXDX:

Disclaimer & DisclosureReport an Issue